Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
HLA gene variant predicts anti-TNF antibodies in Crohn’s
Key clinical point: New research strongly suggests screening for a celiac disease gene variant before starting tumor necrosis factor inhibitors in Crohn’s patients.
Major finding: Overall, the rate of immunogenicity was nearly doubled in HLA-DQA1*05 carriers (hazard ratio, 1.90).
Study details: A genome-wide association in 1,418 biologic-naive Crohn’s patients starting infliximab or adalimumab.
Disclosures: The work was funded by the British Society of Gastroenterology, AbbVie, Merck, Pfizer, and others. The authors disclosed numerous ties to those or other pharmaceutical companies. Two authors were employees of AbbVie, marketer of the branded adalimumab Humira.
Sazonovs A et al. Gastroenterology. 2020 Jan;158(1):189-99.